Suppr超能文献

利多卡因介导的 CPEB3 上调对人肝癌细胞体外增殖的影响。

Effects of Lidocaine-Mediated CPEB3 Upregulation in Human Hepatocellular Carcinoma Cell Proliferation In Vitro.

机构信息

Department of Anesthesiology, The Eye, Ear, Nose and Throat Hospital of Fudan University, Shanghai Medical College of Fudan University, Shanghai, China.

出版信息

Biomed Res Int. 2018 Apr 17;2018:8403157. doi: 10.1155/2018/8403157. eCollection 2018.

Abstract

Lidocaine displays antitumor activity by inducing apoptosis and suppressing tumor growth in human hepatocellular carcinoma (HepG2) cells in vitro. However, the molecular mechanism underlying lidocaine-mediated antitumor activity is unclear. In this study, HepG2 cells were treated with lidocaine, and cell proliferation and colony-forming ability were assessed. The expression level of cytoplasmic polyadenylation element binding protein 3 was detected by real-time quantitative PCR and western blot. Lidocaine treatment resulted in decreased HepG2 cell viability and colony formation in a dose-dependent manner. In hepatocellular carcinoma patient samples, CPEB3 was downregulated and was associated with poor prognosis and high-grade malignancy. Additionally, CPEB3 was a critical mediator of lidocaine-induced repression of HepG2 cell proliferation. These results demonstrated that lidocaine decreased cell viability and colony-forming ability of HepG2 cells by upregulating CPEB3 expression.

摘要

利多卡因通过诱导细胞凋亡和抑制体外人肝癌(HepG2)细胞生长来发挥抗肿瘤活性。然而,利多卡因介导的抗肿瘤活性的分子机制尚不清楚。在这项研究中,用利多卡因处理 HepG2 细胞,并评估细胞增殖和集落形成能力。通过实时定量 PCR 和 Western blot 检测细胞质多聚腺苷酸化元件结合蛋白 3 的表达水平。利多卡因处理呈剂量依赖性降低 HepG2 细胞活力和集落形成。在肝细胞癌患者样本中,CPEB3 下调,与预后不良和高恶性度相关。此外,CPEB3 是利多卡因诱导的 HepG2 细胞增殖抑制的关键介质。这些结果表明,利多卡因通过上调 CPEB3 表达来降低 HepG2 细胞的活力和集落形成能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd3d/5932519/1e868c3bf96f/BMRI2018-8403157.001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验